Besides the prompt and sustained efficacy in disease remission and the safety of bDMARDs in systemic inflammatory conditions [12–14], cardioprotective effects were found in tumor necrosis factor-α (TNF-α) inhibitor treatment [15–18] in patients with RA and psoriasis and were also suggested in certain biological agents, such as tocilizumab and rituximab [19–21]. The gene discussed is TNF; the disease is psoriasis.